TNGX
Tango Therapeutics, Inc.Company with tickers: TNGX
CIK
1819133
CUSIP
87583X109
Shares Outstanding
162,814,649
Website
https://www.tangotx.com
13F Activity (30d)
12 filings
10 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | $0 | USD | 2026-03-31 | 10-Q | 2026-05-13 |
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $48,769,000 | USD | 2026-03-31 | 10-Q | 2026-05-13 |
| Research & Development | $33,534,000 | USD | 2026-03-31 | 10-Q | 2026-05-13 |
| Operating Income | $-48,769,000 | USD | 2026-03-31 | 10-Q | 2026-05-13 |
| Net Income | $-45,514,000 | USD | 2026-03-31 | 10-Q | 2026-05-13 |
| EPS (Basic) | $-0.32 | USD/shares | 2026-03-31 | 10-Q | 2026-05-13 |
| EPS (Diluted) | $-0.32 | USD/shares | 2026-03-31 | 10-Q | 2026-05-13 |
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
By Product & Service (USD)
| Component | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|---|
| Collaboration Revenue | $26,042,000 | $24,860,000 | $31,527,000 | $29,969,000 | $62,384,000 |
| License Revenue | $11,000,000 | — | $5,000,000 | $12,100,000 | — |